Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Rhea-AI Summary
Allogene Therapeutics (Nasdaq: ALLO) expanded its pivotal Phase 2 ALPHA3 trial to South Korea and Australia, growing the study from 60+ to over 80 global sites.
Screening and enrollment are expected to begin in Q2 2026; the study aims for ~220 patients by end-2027 with interim EFS analysis in mid-2027.
Positive
- Trial footprint expanded to >80 global sites
- MRD clearance 58.3% with cema-cel vs 16.7% SOC (first 24 patients)
- No serious treatment-related adverse events reported in interim analysis
- Planned enrollment of ~220 patients by end of 2027
Negative
- Interim data from only 24 patients — small sample for definitive conclusions
- Primary EFS analysis not expected until mid-2028, delaying regulatory clarity
News Market Reaction – ALLO
In the Apr 21 session, ALLO declined 4.13%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.7% during that session. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Preclinical data update | Positive | -4.8% | Nature Communications publication of ALLO-329 preclinical autoimmune disease data. |
| Apr 10 | Interim data preview | Positive | +12.5% | Announcement of upcoming ALPHA3 interim futility analysis data and webcast. |
| Jun 01 | Phase 1 RCC update | Positive | +8.6% | Updated TRAVERSE Phase 1 data for ALLO-316 in advanced RCC at ASCO. |
| Feb 13 | Phase 1 LBCL data | Positive | +44.7% | Publication of durable response data for cema-cel in ALPHA/ALPHA2 LBCL trials. |
| Nov 18 | Preclinical autoimmune data | Positive | -5.3% | Preclinical ALLO-329 autoimmune data presentation at ACR Convergence. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial updates have often led to strong moves, with three positive-aligned reactions and two instances where favorable data coincided with negative price reactions.
Over the past 18 months, ALLO has released multiple clinical trial updates spanning cema‑cel in LBCL and ALLO‑329/ALLO‑316 programs. Notable events include strong Phase 1 ALPHA/ALPHA2 data in Feb 2025 and solid RCC data in Jun 2025, both followed by sizeable gains. Preclinical ALLO‑329 updates have produced mixed reactions. Today’s ALPHA3 global expansion and supportive interim MRD and safety data build directly on the April 2026 futility analysis disclosure for the same pivotal program.
Key Terms
minimal residual disease medical
cytokine release syndrome medical
immune effector cell-associated neurotoxicity syndrome medical
event-free survival medical
biologics license application regulatory
car t medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Expansion Adds to Growing Global Trial Footprint
- Patient Screening and Enrollment Expected to Begin in Q2 2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).
The study, currently enrolling across more than 60 sites in North America, will expand to over 80 global sites with the addition of South Korea and Australia. This growing trial footprint reflects strong interest in ALPHA3 from clinical trial sites.
“Expanding into South Korea and Australia allows us to leverage regions with established clinical research infrastructure and experienced investigators,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “These countries provide high-quality trial environments and efficient healthcare delivery systems. These regulatory approvals, follow our recent interim futility analysis, and we expect this expansion to support the continued enrollment and global development of cema-cel.”
The Company recently announced findings from a planned interim futility analysis of the ALPHA3 trial from the first 24 patients enrolled. In this analysis, cema-cel demonstrated a
About Cemacabtagene Ansegedleucel (cema-cel)
Cemacabtagene ansegedleucel, or cema-cel, is a next generation anti-CD19 AlloCAR T investigational product for the treatment of large B cell lymphoma (LBCL). In June 2022, the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to cema-cel in r/r LBCL. Allogene has oncology rights to cema-cel in the US, EU and UK with options for rights in China and Japan.
About the ALPHA3 Trial
Over 60,000 patients are expected to be treated for LBCL annually in the US, the EU and the UK. While first line (1L) R-CHOP or other chemoimmunotherapy is effective for most patients, approximately
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In some cases, forward-looking statements may be identified by words such as “anticipate,” “expect,” “believe,” “aim,” “plan,” “goal,” “intend,” “seek,” “estimate,” “target,” “potential,” “may,” “could,” “will,” “would,” “should,” “designed to,” “suggest,” “possible,” and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the ongoing Phase 2 ALPHA3 trial of cema-cel, including geographic expansion of the trial, anticipated site activations, and the completion thereof and the timing for data announcements; the potential clinical benefits, safety, tolerability, durability, and efficacy of cema-cel, including its potential to enable earlier intervention in LBCL; its favorable safety profile, and its potential for rapid availability, operational simplicity and outpatient use; the interim futility analysis data providing initial support to suggest that cema-cel may offer a new strategy to treat high-risk patients at the end of first-line treatment; the potential for MRD-guided first-line consolidation to improve outcomes in LBCL, including the potential to eliminate residual disease, and potentially prevent recurrence; the participation from community cancer centers in the Phase 2 ALPHA3 trial underscoring the ability to offer cema-cel in community settings and supporting the potential for broader adoption; and Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, but not limited to, risks and uncertainties inherent in clinical development (including that interim or early data may not be predictive of later or final results and data from a small sample size may not be indicative of results that may be observed in a larger group), patient enrollment and trial execution risks, including risks related to activating and conducting clinical trial sites in additional jurisdictions, uncertainties related to MRD testing and its clinical significance and reliability, including whether MRD is predictor of relapse in LBCL or MRD clearance improvements translate to meaningful clinical benefits, the occurrence of adverse safety events, regulatory risks and uncertainties, manufacturing and CMC risks, reliance on third parties and licensors, competitive developments, intellectual property and contractual risks, and financial risks, including the need for additional capital. These and other risks and uncertainties are described more fully in Allogene’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, and other filings that Allogene may make from time to time with the SEC. All forward-looking statements in this press release speak only as of the date of this press release, and Allogene undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to Servier. Servier has granted Allogene exclusive rights to cema-cel in the U.S., all EU Member States and the United Kingdom.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
